Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
(Nature, 2014) used an antisense oligonucleotide to knock down NNMT in mice and reported reduced fat-mass gain, better glucose tolerance, and lower liver triglycerides the founding paper for the whole NNMT-inhibitor field
* Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies
Loading No Records Found Sorry, no records were found
These filings help safeguard the companys position in the market and highlight its ongoing efforts to develop long-term treatments for obesity and related metabolic conditions
Use caution with insulin/sulfonylureas (hypoglycemia), a history of gallbladder disease, diabetic retinopathy, or significant kidney disease
US$ 26.50
US$ 20.97
